Adocia
About
History
Management
Board of directors
Advisory board
Products and platforms
Pipeline
Technology Platforms
Careers
The « Adocians »
HR policy
Work environment
Join us
Partnering
Investors
Media
Contact
Contact us
Map and accessibility
Investors
Regulated information
Stock information
Corporate governance
General meeting
Media
Press releases
Media
EN
FR
Number of shares and voting rights of ADOCIA as of May 31, 2020
Previous article
ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience.
Next article
Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtual experience
